Ignite Creation Date:
2024-05-06 @ 3:21 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02279004
Status:
RECRUITING
Last Update Posted:
2023-12-12
First Post:
2014-10-28
Brief Title:
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib However tumor genotyping can be slow and cumbersome and is limited by availability of tumor biopsy tissue for testing The aim of this study is to prospectively evaluate a blood-based genotyping tool that can quantify the presence of oncogenic mutations EGFR KRAS BRAF in patients with lung cancer and melanoma This assay is being studied both as a diagnostic tool for classifying patient genotype and a serial measurement tool for quantification of response and progression on therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None